Search Results

KAHR and the Myeloma Investment Fund announced that the MIF has invested in KAHR to explore the potential of DSP107, KAHR’s lead immunotherapy drug candidate, for the treatment of multiple myeloma.

KAHR today announced positive results from the dose escalation Phase I study of DSP107 in combination with atezolizumab (anti-PD-L1) in patients with advanced solid tumors.

KAHR , a clinical-stage cancer immunotherapy company developing novel bi-functional fusion proteins, today announced the appointment of Jennifer Minai-Azary to its Board of Directors. The appointment is effective immediately.

Samsung Biologics, the world’s leading contract development and manufacturing organization, signed a strategic partnership with KAHR Medical Ltd., a cancer immunotherapy company developing novel multifunctional immune-recruitment proteins.

KAHR, today announced that the first patient has been dosed in a Phase 1b clinical trial of DSP107.

KAHR, today announced publication of preclinical data supporting the development of DSP107, a potential first-in-class investigational CD47x41BB targeting fusion protein designed to activate both the innate and adaptive immune systems, as a monotherapy and in combination for the treatment of cancer.

KAHR and Cancer Focus Fund, LP, a unique venture capital fund established in collaboration with The University of Texas MD Anderson Cancer Center to provide funding and clinical expertise to advance promising cancer therapies, announced that Cancer Focus Fund is investing $5 million to finance a clinical trial of KAHR’s lead anti-CD47 candidate, DSP107, in blood cancers.

KAHR Medical today announced the company’s participation in Oppenheimer’s Private Life Sciences Company Call Series taking place virtually August 17-19, 2020.

KAHR, a cancer immunotherapy company developing novel multifunctional immuno-recruitment proteins, announced the first closing of an investment round raising $46.5 million.